Gene Expression, Immune Response and In-Vivo

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Gene Expression

Immune Response

In-Vivo

Advances in Genetic Medicine May Be Outpacing Some Clinicians’ Understanding, But Pharmaceutical Marketers Can Do Much to Address the Problem

Pharma Marketing Network

DECEMBER 21, 2020

those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies. Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e.,

Genetics

Genetics Medicine Gene Therapy Marketing

Tezepelumab granted Priority Review by U.S. FDA

The Pharma Data

JULY 8, 2021

Many patients with severe asthma have an inadequate response to currently available biologics and oral corticosteroids and thus fail to achieve asthma control.(2,6,9) Amgen (NASDAQ:AMGN) announced that the U.S. Tezepelumab is being developed by Amgen in collaboration with AstraZeneca. Reese, M.D., About Severe Asthma.

Allergies

Allergies Trials In-Vivo Medicine

Clinical Research Informer

Advances in Genetic Medicine May Be Outpacing Some Clinicians’ Understanding, But Pharmaceutical Marketers Can Do Much to Address the Problem

Tezepelumab granted Priority Review by U.S. FDA

Stay Connected